China Insulin Glargine Market Size
Synopsis With the improvement of people’s living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making t the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has become a heavy burden on individuals, families, society and governments. According to statistics from DIF (International Diabetes Federation), the global prevalence rate of diabetes among adults aged 20 to 79 was 8. 3% in 2013.
The number of diabetes patients has reached 382 million, of which 80% are from medium and low income countries where it is still rising rapidly. Inquire this Report before buying @ http:// www. chinamarketresearchreports. Com/contacts/inquire-before-buy. PH? Name-”114725 . It is estimated that by 2035 there will be nearly 592 million people worldwide suffering from diabetes. In the evaluation of diabetes incidence and its trend among various countries and regions, China ranked the first with 98. 4 million diabetes patients in 2013, followed by India (65. Million), the U. S. A. (24. 4 million), Brazil (1 1. 9 million) and Russia (10. 9 million). DIF estimates that the number of aviates patients in China will reach 143
Need essay sample on "China Insulin Glargine Market Size"? We will write a custom essay sample specifically for you for only $ 13.90/page
It was approved for use by FDA (Food and Drug Administration) in April 2000 and MEME (European Medicines Evaluation Agency) in June 2000. As there is no apparent peak in long term use of insulin glaring, it has become the most widely used insulin in the United States. In China, the third generation insulin is under promotion. Because of the relatively high price, it is mainly used in first tier cities at present. The second and third generation insulin will be faced with a market pattern of dislocation competition. Complete report spread across [40] pages available @ http://www. hinamarketresearchreports. Com/ 114725. HTML . Read more on “Investigation Report on China Insulin Glaring Market, 2009-2018” report below. Based on Crib’s research about certain sample hospitals in China, the CARR (compound annual growth rate) of sales value of insulin glaring in Chinese sample hospital market exceeded 70% from 2005 to 2013. Human insulin is produced through genetic engineering methods, so a relatively high threshold of production technology is formed. Compared with other genetic engineering drugs,